Insider Buying: Indivior (NASDAQ:INDV) CAO Buys $53,535.00 in Stock

Indivior PLC (NASDAQ:INDV) CAO Woodrow Anderson purchased 1,500 shares of Indivior stock in a transaction that occurred on Thursday, August 27th. The stock was bought at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the purchase, the chief accounting officer directly owned 27,638 shares in the company, valued at $986,400.22. This trade represents a 5.74% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Indivior Stock Down 1.5%

INDV traded down $0.53 on Thursday, reaching $35.30. 1,220,385 shares of the company traded hands, compared to its average volume of 2,195,336. Indivior PLC has a one year low of $22.22 and a one year high of $42.81. The firm has a fifty day simple moving average of $39.46 and a two-hundred day simple moving average of $36.00. The company has a market cap of $4.17 billion, a P/E ratio of 12.65 and a beta of 0.86.

Indivior (NASDAQ:INDV) last issued its earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. The business had revenue of $343.00 million for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. On average, equities analysts forecast that Indivior PLC will post 3.66 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on INDV. Craig Hallum reissued a “buy” rating and issued a $53.00 price objective on shares of Indivior in a research note on Tuesday, August 4th. Barclays decreased their target price on Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday, August 5th. Weiss Ratings cut Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, August 21st. Finally, Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.17.

Institutional Investors Weigh In On Indivior

Hedge funds have recently modified their holdings of the business. Quarry LP purchased a new stake in shares of Indivior in the 3rd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd increased its holdings in Indivior by 72.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after buying an additional 460 shares during the period. Rockefeller Capital Management L.P. raised its stake in Indivior by 512.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after buying an additional 1,076 shares in the last quarter. TD Waterhouse Canada Inc. bought a new position in Indivior in the second quarter worth approximately $63,000. Finally, GAMMA Investing LLC purchased a new stake in Indivior during the second quarter worth $66,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.